 |
 
|
|
The partners of Best Practice are among the world's leading minds in neuropsychiatry. Together,
they bring over 100 years of clinical research experience and service to the pharmaceutical
industry and government.
Our partners have served Presidents of the United States, the United Nations, the FDA, the National
Institutes of Health, and pharmaceutical and biotech firms of all sizes. Among them, our partners
have published almost a thousand books and articles; their books are some of the basic texts in their
fields. They have served on the editorial boards of the opinion making journals most read by their colleagues,
and they have won the most prestigious awards offered in their fields.
Our partners and affiliates have no peer in the field. Our partners identify the right people, bring
together the right team, and manage efforts on behalf of our clients. Best Practice has the long-term
relationships and collaborations to know where to go, whom to ask, and how to get the response our
clients need.
|
|
|
Roger E. Meyer, MD, Chairman, CEO
Dr. Roger E. Meyer has directed NIH-funded research centers at Harvard University and the University of Connecticut. He has also held decanal and senior leadership positions at two major medical schools.
View Biography
|
|
|
|
Daniel F. Bush, PhD, Partner, Senior Vice President
Dr. Daniel F. Bush, formerly head of the CNS group at Quintiles and an expert in clinical drug development,
has served in many leading pharmaceutical companies and, currently, serves as chairman of the Government / Industry Collaboration Committee
for the NIMH funded MATRICS.
View Biography
|
|
|
|
Frederick K. Goodwin, MD, Partner
Dr. Frederick K. Goodwin, one of the most cited psychopharmacologists in the
world, is a leading international authority on the research and treatment of depression and
manic-depressive illness.
View Biography
|
|
|
|
Thomas Roth, PhD, Partner
Dr. Thomas Roth, one of the leading authorities on sleep and sleep
medicine in the world, has examined sleep loss, sleep fragmentation, sleep pathologies, and
the effects of pharmacologic agents on sleep-wake function.
View Biography
|
|
|
|
|
